Identifying Genetic Risk for Late-onset Alzheimer's Disease: The GERAD Consortium

Lead Research Organisation: Cardiff University
Department Name: School of Medicine

Abstract

Alzheimer?s disease (AD) is the most common form of dementia whose numbers will double in the next generation resulting in over one million sufferers in the UK alone. It is vital we understand the causes of AD quickly to allow the development of preventative and therapeutic interventions. We have good evidence that genes play significant roles in AD development and that there are several remaining to be found. This research study will use new technological advances to test the influence of every human gene on the risk of developing AD. The success of this approach depends on using very large samples of AD cases and controls. This study is the largest genome-wide association study (GWAS) of AD world-wide and is anticipated to identify 20 new risk genes and disease pathways AD risk genes pinpoint primary biological processes which trigger disease development.

Technical Summary

Alzheimer‘s disease (AD) is a common, heritable, genetically complex disorder. Genome-wide association studies (GWAS) have succeeded in identifying over 400 genetic variants contributing to complex phenotypes, in less than two years. Recently, our consortium performed a GWAS in 16,000 AD and control samples, which succeeded in identifying two new susceptibility genes (CLU: p= 8.5 x10-10, odds ratio (OR) = 0.86 & PICALM: p= 1.3 x10-9, OR = 0.86), provided strong evidence for the existence of several more (13 variants observed p 1 x 10-5 , 4 expected by chance: p= 7.5 x 10-6)and confirmed a third susceptibility gene CR1. We will undertake a powerful GWAS (+55,000 individuals) of AD, aiming to identify 10 new susceptibility genes contributing to disease risk, modifying age at onset or contributing to copy number variation. Findings will be screened for AD susceptibility pathways and tested for relationships with clinical symptoms. This proposal will produce a definitive study of common genetic risk in AD and will deliver around 20 new susceptibility genes, CNVs and pathways in 2 years. Identifying new susceptibility genes will pinpoint primary causal pathways to disease and provide the basis for future preventative and therapeutic interventions, contribute to early susceptibility testing and increase UK research capacity.

Organisations

Publications


10 25 50
Baig S (2012) Clusterin mRNA and protein in Alzheimer's disease. in Journal of Alzheimer's disease : JAD
Belbin O (2011) A multi-center study of ACE and the risk of late-onset Alzheimer's disease. in Journal of Alzheimer's disease : JAD
Benitez BA (2014) Missense variant in TREML2 protects against Alzheimer's disease. in Neurobiology of aging
Brossman B (2012) Development of the Huntington disease work function scale. in Journal of occupational and environmental medicine
Chouraki V (2016) Evaluation of a Genetic Risk Score to Improve Risk Prediction for Alzheimer's Disease. in Journal of Alzheimer's disease : JAD
 
Description Chief Scientific Advisor to Alzheimer's Research Trust
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Participation in advisory committee
 
Description Chief Scientific Advisor to Alzheimer's Research UK
Geographic Reach National 
Policy Influence Type Participation in advisory committee
 
Description Department of Health Advisory Group on Dementia
Geographic Reach National 
Policy Influence Type Gave evidence to a government review
 
Description Department of Health Advisory Group on Dementia
Geographic Reach National 
Policy Influence Type Membership of a guidance committee
 
Description Department of Health Advisory Group on Dementia
Geographic Reach National 
Policy Influence Type Participation in advisory committee
 
Description Welsh Assembly Government Advisory Group on Dementia
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Participation in a advisory committee
 
Description Alzheimer's Research UK Network Cardiff Grant
Amount £69,000 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 09/2011 
End 08/2014
 
Description Brains for Demention Research Programme
Amount £225,571 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 04/2013 
End 03/2018
 
Description Brains for dementia research
Amount £161,915 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start  
 
Description Clinical collection supply agreement to investigate the genetics of Alzheimer's disease/Glaxosmithkline Research & Development
Amount £532,000 (GBP)
Organisation GlaxoSmithKline (GSK) 
Sector Private
Country Global
Start  
 
Description Defining genetic, polygenic and environmental risk for Alzheimer's disease using multiply powerful cohorts, focussed epigenetics and stem cells
Amount £810,998 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 05/2014 
End 04/2017
 
Description Dyslexia genes and neurobiological pathways (NEURODYS)
Amount £251,460 (GBP)
Organisation European Commission (EC) 
Sector Public
Country European Union (EU)
Start  
 
Description Evaluation of candidate genomic regions to determine genetic pedisposition in populations of Alzheimer's patients
Amount £168,514 (GBP)
Organisation The Wellcome Trust Ltd 
Sector Charity/Non Profit
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start  
 
Description Grant for the establishment of an ART AD research centre
Amount £203,000 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start  
 
Description IDEA - Integrated DEmentiA research enviornment
Amount £1,882,982 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 04/2015 
End 03/2016
 
Description Industrial Collaborative Studentship - A novel approach to identifying new susceptibility genes for late on-set Alzheimer's disease and its sub components
Amount £52,645 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start  
 
Description International Alzheimer's disease genetics consortium
Amount £11,501 (GBP)
Organisation Alzheimer’s Society 
Sector Charity/Non Profit
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 10/2010 
End 09/2012
 
Description NEURODEM/National Assembly for Wales via Bangor University
Amount £41,674 (GBP)
Organisation National Institute for Social Care and Health Research Clinical Research Centre (NISCHR CRC) 
Sector Public
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start  
 
Description Powerful study of rare variants in Alzheimer's disease (R Sims)
Amount £200,000 (GBP)
Organisation Alzheimer’s Society 
Sector Charity/Non Profit
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 04/2012 
End 02/2016
 
Description Translating new susceptibility genes for Alzheimer's Disease through clinical characterisation and epidemiology/Welsh Assembly Government
Amount £148,348 (GBP)
Organisation National Institute for Social Care and Health Research Clinical Research Centre (NISCHR CRC) 
Sector Public
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start  
 
Description Translating the effects of new susceptibility genes for AD into disease mechanisms and potentia
Amount £205,025 (GBP)
Organisation National Institute for Social Care and Health Research Clinical Research Centre (NISCHR CRC) 
Sector Public
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 03/2012 
End 02/2014
 
Description Wellcome Trust Project Grant (A Powerful, Genome-Wide Association Scan for Susceptibility Genes for late-onset Alzheimer's disease)
Amount £286,504 (GBP)
Organisation The Wellcome Trust Ltd 
Sector Charity/Non Profit
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start  
 
Title Brain Bank - Alzheimers 
Description We have recently created a brain bank based upon the longitudinal sample, to provide the wider research community with multiple tissue samples on well characterised individuals. 
Type Of Material Biological samples 
Year Produced 2007 
Provided To Others? Yes  
Impact Multiple publications and media coverage 
 
Title Brains for Dementia Research 
Description Brains; cases and controls 
Type Of Material Biological samples 
Year Produced 2007 
Provided To Others? Yes  
Impact unknown 
 
Title Human Stem Cell Modelling of Brain Disease 
Description Cellular models in vitro 
Type Of Material Model of mechanisms or symptoms - in vitro 
Provided To Others? No  
Impact unknown 
 
Title Polygenic score 
Description With 80,000 variants included to create a measure of risk of Alzheimer's disease, the polygenic score is an excellent predictive tool to determine case/control status with high accuracy. The polygenic score encompasses the majority of genetic risk of disease, and can be fine-tuned to identify the pathways involved in disease, for example, immune cell activity or endocytosis. 
Type Of Material Model of mechanisms or symptoms - human 
Year Produced 2016 
Provided To Others? Yes  
Impact We are working to translate this method from the basic science environment in which it was created into a predictive tool used to select participants for clinical trials, based on their disease status and type. We are currently in discussions with a number of potential collaborators to take this forward. 
 
Title GERAD GWAS 
Description Genome-wide association study data of over 3,000 AD cases and 7,000 controls 
Type Of Material Database/Collection of data 
Year Produced 2009 
Provided To Others? Yes  
Impact multiple publications 
 
Title IGAP dataset 
Description Mega-meta analysis data of over 17,000 AD cases and 30,000 controls 
Type Of Material Database/Collection of data 
Year Produced 2013 
Provided To Others? Yes  
Impact Lambert et al. 2013 (PMID:24162737), Escott-Price et al. 2014(in press), Farrer et al. 2014 (submitted) 
 
Description Caerphilly Cohort 
Organisation Cardiff University
Department Cardiff University School of Medicine
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution AD expertise, Genotyping, Data analysis, study design
Collaborator Contribution DNA, Epidemiological data, data analysis, study design
Impact unknown
Start Year 2012
 
Description Caerphilly Cohort 
Organisation Institute of Public Health Cambridge
Department Cognitive Function and Ageing Study (CFAS)
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution AD expertise, Genotyping, Data analysis, study design
Collaborator Contribution DNA, Epidemiological data, data analysis, study design
Impact unknown
Start Year 2012
 
Description Caerphilly Cohort 
Organisation University of Bristol
Department Avon Longitudinal Study of Parents and Children (ALSPAC)
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution AD expertise, Genotyping, Data analysis, study design
Collaborator Contribution DNA, Epidemiological data, data analysis, study design
Impact unknown
Start Year 2012
 
Description Clinical collection supply agreement to investigate the genetics of Alzheimer's disease 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution We collected 200 AD cases with full clinical work up including volumetric neuroimaging and DNA sampling.
Collaborator Contribution GSK funded the collection and storage of DNA samples and clinical and neuroimaging measures on 200 Alzheimer's disease cases in the early stages of disease.
Impact 17998437 19013250
 
Description Eli Lilly Collaboration 
Organisation Cardiff University
Department Cardiff University School of Medicine
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Access to patient bio-samples, co-directs study design
Collaborator Contribution scientific input, co-direct study design, funding
Impact unknown
Start Year 2012
 
Description Eli Lilly Collaboration 
Organisation Eli Lilly & Company Ltd
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Private 
PI Contribution Access to patient bio-samples, co-directs study design
Collaborator Contribution scientific input, co-direct study design, funding
Impact unknown
Start Year 2012
 
Description Finding genes for late onset Alzheimer's disease: Collaboration between Washington University, NIMH, Cardiff University and Celera Diagnostics 
Organisation Quest Diagnostics
Department Celera Diagnostics
Country United States of America 
Sector Private 
PI Contribution We undertook a genomewide association study of Alzheimer's disease using genetic pooling and also tested associations with candidate genes. The Celera Diagnostics through a sub-contract with MERCK paid for the genomewide association genotyping. Our group took the lead on some studies and contributed samples and intellectual input on others but at all stages all decisions about research design etc were undertaken jointly in a full collaborative fashion. This built on a previous collaboration between ourselves and Allison Goates group from Washington University which spanned over a decade.
Collaborator Contribution Our collaborative group including Celera Diagnostics, Allison Goate and John Hardys research groups undertook a genomewide association study of Alzheimer's disease using genetic pooling and also tested associations with candidate genes. Celera Diagnostics through a sub-contract with MERCK paid for the genomewide association genotyping. Our group took the lead on some studies and contributed samples and intellectual input on others but at all stages all decisions about research design etc were undertaken jointly in a full collaborative fashion. This built on a previous collaboration between ourselves and Allison Goates group from Washington University which spanned over a decade.
Impact 17949987 17492769 17725986 18063669 16161859 16385451 16278862 16847012 17317784
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Brigham Young University
Country United States of America 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Cardiff University
Department MRC Centre for Neuropsychiatric Genetics and Genomics
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Faculty of Medical and Human Sciences
Department Neuroscience Research Institute (NRI)
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Faculty of Medicine
Department Clinical and Experimental Sciences
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Free University of Berlin
Country Germany, Federal Republic of 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Friedrich-Alexander University Erlangen-Nuremberg
Department Department of Psychiatry
Country Germany, Federal Republic of 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Goethe University Frankfurt
Country Germany, Federal Republic of 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Helmholtz Association of German Research Centres
Department German Research Centre for Environmental Health
Country Germany, Federal Republic of 
Sector Public 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation King's College London (KCL)
Department Institute of Psychiatry (IoP)
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Ludwig Maximilian University of Munich (LMU Munich)
Department Department of Neurology
Country Germany, Federal Republic of 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Mayo Foundation for Medical Education and Research (MFMER)
Country United States of America 
Sector Charity/Non Profit 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation NIHR Oxford Biomedical Research Centre
Department Oxford Project to Investigate Memory and Ageing (OPTIMA)
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation National Institutes of Health (NIH)
Country United States of America 
Sector Public 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Queen's University of Belfast
Department Aging group
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Research Institute for Neurodegerative Diseases (DZNE)
Country Germany, Federal Republic of 
Sector Public 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Ruprecht Karl University of Heidelberg (Ruprecht-Karls-Universität Heidelberg)
Department Central Institute of Mental Health Mannheim
Country Germany, Federal Republic of 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation School of Biology Nottingham
Department Centre for Genetics and Genomics
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation School of Clinical Sciences Bristol
Department Dementia Research Group
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation The Wellcome Trust Sanger Institute
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Charity/Non Profit 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University College London (UCL)
Department MRC Prion Unit and the Dementia Research Centre
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University College London (UCL)
Department UCL Institute of Neurology
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University Duisburg-Essen
Country Germany, Federal Republic of 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University of Bonn
Department Department of Psychiatry
Country Germany, Federal Republic of 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University of Cambridge
Department Institute of Public Health Cambridge
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University of Dublin
Department Trinity College Dublin
Country Ireland, Republic of 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University of Freiburg
Country Germany, Federal Republic of 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University of Hamburg
Country Germany, Federal Republic of 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University of Zurich (Universität Zürich UZH)
Department Functional Genomics Centre Zurich (FGCZ)
Country Switzerland, Swiss Confederation 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Washington University at St Louis
Country United States of America 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD Exome Chip Consortium 
Organisation Autonomous University of Madrid (Universidad Autónoma de Madrid UAM)
Country Spain, Kingdom of 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation Brigham Young University
Country United States of America 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation Cardiff University
Department Cardiff University School of Medicine
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation Faculty of Medicine
Department Clinical and Experimental Sciences
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation Fondazione Santa Lucia
Country Italy, Italian Republic 
Sector Hospitals 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation Hospital de Sant Pau
Country Spain, Kingdom of 
Sector Hospitals 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation Ludwig Maximilian University of Munich (LMU Munich)
Country Germany, Federal Republic of 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation Neuroscience; IOP
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation Queen's University of Belfast
Department Aging group
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation Saarland University
Country Germany, Federal Republic of 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation School of Biology Nottingham
Department Centre for Genetics and Genomics
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation UCL Institute of Neurology
Department Prion Unit
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation University of Bonn
Department Department of Psychiatry
Country Germany, Federal Republic of 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation University of Cantabria
Country Spain, Kingdom of 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation University of Navarra
Country Spain, Kingdom of 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation University of Oviedo
Country Spain, Kingdom of 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation University of Oxford
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation University of Washington
Country United States of America 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description Genome-wide Association Studies 
Organisation National Center for Biotechnology Information (NCBI)
Department Genome-wide Association Study Collaboration
Country United States of America 
Sector Academic/University 
PI Contribution Led and co-ordinated the study that involved the work of the following collaborators: 1 MRC Centre for Neuropsychiatric Genetics and Genomics, Department of Psychological Medicine and Neurology, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK. 2 NIHR Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust and Institute of Psychiatry, Kings College, London, UK. 3 Department of Neuroscience, Institute of Psychiatry, Kings College, London, UK. 4 Institute of Public Health, University of Cambridge, Cambridge, UK. 5 Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK. 6 Mercer's Institute for Research on Aging, St. James Hospital and Trinity College, Dublin, Ireland. 7 Institute of Genetics, Queen's Medical Centre, University of Nottingham, NG7 2UH, UK. 8 Ageing Group, Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, UK. 9 Division of Clinical Neurosciences, School of Medicine, University of Southampton, Southampton, UK. 10 Clinical Neuroscience Research Group, Greater Manchester Neurosciences Centre, University of Manchester, Salford, UK. 11 Oxford Project to Investigate Memory and Ageing (OPTIMA), University of Oxford, Level 4, John Radcliffe Hospital, Oxford OX3 9DU, UK. 12 Dementia Research Group, University of Bristol Institute of Clinical Neurosciences, Frenchay Hospital, Bristol, UK. 13 Department of Molecular Neuroscience and Reta Lilla Weston Laboratories, Institute of Neurology, London, UK. 14 MRC Prion Unit, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK. 15 Dementia Research Centre, Department of Neurodegenerative Diseases, University College London, Institute of Neurology, London, UK. 16 Department of Psychiatry, University of Bonn, Sigmund-Freud-Str. 25, D-53105 Bonn, Germany. 17 Institute of Primary Medical Care, University Medical Center Hamburg-Eppendorf, Germany. 18 Department of Psychiatry, Charité Berlin, Germany. 19 Department of Psychiatry and Psychotherapy, University of Erlangen-Nüremberg, Germany. 20 LVR-Hospital Essen, Department of Psychiatry and Psychotherapy, University Duisburg-Essen, Germany. 21 Institute for Stroke and Dementia Reserach, Klinikum der Universität München, Marchioninistr. 15, 81377, Munich, Germany. 22 Department of Neurology, Klinikum der Universität München, Marchioninistr. 15, 81377, Munich, Germany. 23 Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Square J5, D-68161 Mannheim, Germany. 24 Discipline of Psychiatry, School of Medicine and Trinity College Institute of Neuroscience, Laboratory of Neuroimaging & Biomarker Research, Trinity College, University of Dublin, Ireland. 25 Alzheimer Memorial Center and Geriatric Psychiatry Branch, Department of Psychiatry, Ludwig-Maximilian University, Munich, Germany. 26 Centre for Geriatric Medicine and Section of Gerontopsychiatry and Neuropsychology, Medical School, University of Freiburg, Germany. 27 Departments of Psychiatry, Neurology and Genetics, Washington University School of Medicine, St Louis, MO 63110, US. 28 Department of Biology, Brigham Young University, Provo, UT, 84602, USA. 29 Neurodegenerative Brain Diseases group, Department of Molecular Genetics, VIB, Antwerpen, Belgium. 30 Institute Born-Bunge and University of Antwerp; Antwerpen, Belgium. 31 Memory Clinic and Department of Neurology, ZNA Middelheim, Antwerpen, Belgium. 32 Department of Mental Health Sciences, University College London, UK. 33 The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK. 34 MRC Centre for Neurodegeneration Research, Department of Clinical Neuroscience, King's College London, Institute of Psychiatry, London, SE5 8AF, UK. 35 3rd Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece. 36 Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, 20892, USA. 37 Department of Genomics, Life & Brain Center, University of Bonn, Sigmund-Freud-Str. 25, D-53127 Bonn, Germany. 38 Institute of Human Genetics, University of Bonn, Wilhelmstr. 31, D-53111 Bonn, Germany. 39 Institute for Medical Informatics, Biometry and Epidemiology, University Hospital of Essen, University Duisburg-Essen, Hufelandstr. 55, D-45147 Essen, Germany. 40 Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, 85764 Neuherberg, Germany. 41 Institute of Medical Informatics, Biometry and Epidemiology, Chair of Epidemiology, Ludwig-Maximilians-Universität, Munich, Germany. 42 Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, Florida 32224, USA. 43 Division of Biomedical Statistics and Informatics, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
Collaborator Contribution This group of 45 collaborators all contributed towards the centres Genome-wide association study
Impact The study, published in Nature Genetics (PubMed ID 19734902), has uncovered two new genes associated with Alzheimer's disease. Previously only one gene, APOE4, had been shown to be a risk factor for Alzheimer's disease. The study reveals, for the first time, that two further genes, CLU and PICALM, are related to Alzheimer's disease. This has led to worldwide media coverage. The data produced is still used in new studies with requests coming in to the host institution every few weeks.
Start Year 2009
 
Description International Genomics of Alzheimer's Project (IGAP) 
Organisation Boston University
Country United States of America 
Sector Academic/University 
PI Contribution Co-leadership, management, DNA from AD cases and controls, GWAS data from AD cases and controls, data analysis and joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation, data analysis
Impact papers in progress
Start Year 2012
 
Description International Genomics of Alzheimer's Project (IGAP) 
Organisation Genetic and Environmental Risk in Alzheimer's Disease (GERAD)
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Charity/Non Profit 
PI Contribution Co-leadership, management, DNA from AD cases and controls, GWAS data from AD cases and controls, data analysis and joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation, data analysis
Impact papers in progress
Start Year 2012
 
Description International Genomics of Alzheimer's Project (IGAP) 
Organisation University of Lille
Country France, French Republic 
Sector Academic/University 
PI Contribution Co-leadership, management, DNA from AD cases and controls, GWAS data from AD cases and controls, data analysis and joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation, data analysis
Impact papers in progress
Start Year 2012
 
Description International Genomics of Alzheimer's Project (IGAP) 
Organisation University of Pennsylvania School of Medicine
Department Alzheimer's Disease Genetics Consortium (ADGC)
Country United States of America 
Sector Learned Society 
PI Contribution Co-leadership, management, DNA from AD cases and controls, GWAS data from AD cases and controls, data analysis and joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation, data analysis
Impact papers in progress
Start Year 2012
 
Description MRC AD Cohort 
Organisation King's College London (KCL)
Department Institute of Psychiatry (IoP)
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution We contributed DNA, clinical follow up information, genotyping and other laboratory work and complex data analysis.
Collaborator Contribution The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.
Impact 16970641 17322133 17530621 17440948 17440933 17373700 17999207 18163421
 
Description MRC AD Cohort 
Organisation Medical Research Council (MRC)
Department MRC Centre for Developmental Neurobiology
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution We contributed DNA, clinical follow up information, genotyping and other laboratory work and complex data analysis.
Collaborator Contribution The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.
Impact 16970641 17322133 17530621 17440948 17440933 17373700 17999207 18163421
 
Description MRC AD Cohort 
Organisation School of Clinical Medicine
Department Department of Medical Genetics
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution We contributed DNA, clinical follow up information, genotyping and other laboratory work and complex data analysis.
Collaborator Contribution The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.
Impact 16970641 17322133 17530621 17440948 17440933 17373700 17999207 18163421
 
Description MRC AD Cohort 
Organisation School of Clinical Medicine
Department Department of Public Health and Primary Care
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution We contributed DNA, clinical follow up information, genotyping and other laboratory work and complex data analysis.
Collaborator Contribution The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.
Impact 16970641 17322133 17530621 17440948 17440933 17373700 17999207 18163421
 
Description MRC AD Cohort 
Organisation University of Dublin
Department Trinity College Dublin
Country Ireland, Republic of 
Sector Academic/University 
PI Contribution We contributed DNA, clinical follow up information, genotyping and other laboratory work and complex data analysis.
Collaborator Contribution The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.
Impact 16970641 17322133 17530621 17440948 17440933 17373700 17999207 18163421
 
Description Population Genetics Techologies (PGT) 
Organisation Cardiff University
Department Cardiff University School of Medicine
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution DNA, AD expertise, data analysis
Collaborator Contribution Next generation sequencing service, bioinformatic study design, data analysis
Impact unknown
Start Year 2011
 
Description Population Genetics Techologies (PGT) 
Organisation Population Genetics Technologies Ltd
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Private 
PI Contribution DNA, AD expertise, data analysis
Collaborator Contribution Next generation sequencing service, bioinformatic study design, data analysis
Impact unknown
Start Year 2011
 
Description Translating the effects of new susceptibility genes for AD into disease mechanisms and potential drug screening 
Organisation Cardiff University
Department Cardiff University School of Medicine
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution AD expertise, genotying, data analysis, study design, co-supervision of research fellow Amy Gerrish
Collaborator Contribution Functional expertise, study design, co-supervision of research fellow Amy Gerrish
Impact unknown
Start Year 2012
 
Description Translating the effects of new susceptibility genes for AD into disease mechanisms and potential drug screening 
Organisation Severnside Alliance for Translational Research (SARTRE)
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution AD expertise, genotying, data analysis, study design, co-supervision of research fellow Amy Gerrish
Collaborator Contribution Functional expertise, study design, co-supervision of research fellow Amy Gerrish
Impact unknown
Start Year 2012
 
Description Using worms and flies to screen human genes associated with Alzheimer's disease 
Organisation University of Cambridge
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution AD expertise, GWAS data
Collaborator Contribution Functional expertise, Model organisms
Impact unknown
Start Year 2008
 
Description Using worms and flies to screen human genes associated with Alzheimer's disease 
Organisation University of Manchester
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution AD expertise, GWAS data
Collaborator Contribution Functional expertise, Model organisms
Impact unknown
Start Year 2008
 
Title Diagnosis of Alzheimer's Disease 
Description The work has also been published and has achieved a huge amount of media coverage. This discovery of three further genes associated with Alzheimer's disease could provide valuable new leads in the race to find treatments and possibly cures for the devastating condition. This patent application resulted from Julie Williams, Professor of Neuropsychological Genetics and Professor Mike Owen, Professor and Head of MRC Centre, completing the largest-ever joint Alzheimer's disease genome-wide association study (GWAS) involving 16,000 individuals. The patenting of theseSNPS is still in progress and a reveiew is currently underway to identify the best route to exploitation of the technology. 
IP Reference WO2011001135; NZ 596614; CAN 2,766,876; JP 2012-516841 and JP 2013-164509 ;AUS 201001208; US 13/376,485 and US 13/886,473; EP 10747062.7; CN 201080029259.9 and CN 201310280889.9; HK 12110195.8; UK 2766876 
Protection Patent granted
Year Protection Granted 2012
Licensed No
Impact This has had huge worldwide impact through media coverage and was originally highlighted in the press with the discovery of an additional 5 genes. We are currently in the process of seeking a licencee for the patented technology which encompasses a diagnostic test for the protected gene SNPs. Recent advances include generation of a polygenic score including the licensed SNPs for the detection of AD risk. We are working together with industry on basic genetic testing, cohort studies, cognitive test providers and pathway specific therapies for new ways in which to combat Alzheimer's disease.
 
Description 11 new susceptibility genes linked with Alzheimer's disease 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact In the largest ever study of its kind, an international collaboration of scientists, jointly led by Cardiff, has uncovered 11 new susceptibility genes linked with Alzheimer's disease.


Worldwide TV and Newspaper Coverage received
Year(s) Of Engagement Activity 2013
 
Description 2 new genetic variations linked with Alzheimer's 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact An international collaboration of scientists, including expertise from Cardiff University, has uncovered two new genetic variations linked with Alzheimer's, opening up new research avenues into the disease. The two newly discovered genetic variations do not predict a person's risk of developing Alzheimer's, but the authors of the paper, which appears in The Journal of the American Medical Association (JAMA) speak of new valuable insights for scientists working on the disease. Professor Julie Williams, Cardiff University, is a principal investigator of the study, led by Professor Monique Breteler, University Medical Center Rotterdam. The research also builds on the discovery led by Professor Williams last year of the first new genes associated with Alzheimer's in a generation.


Unknown
Year(s) Of Engagement Activity 2010
 
Description 5 new Alzheimer's genes 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact A leading University scientist's search for factors that increase the risk of developing Alzheimer's has uncovered five new genes to help pinpoint what's going wrong in the brain. Professor Julie Williams from the University's MRC Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, has identified an additional five new genes - bringing the total number of genes that increase the risk of developing Alzheimer's to ten. (BBC Radio 4, Today programme, BBC Radio Wales, Good Morning Wales, BBC Wales Breakfast News, ITV Wales Breakfast News; BBC On-line, 4.4.2011, www.bbc.co.uk/news/health-12937131; The Mirror, 4.4.11, www.mirror.co.uk/news/top-stories/2011/04/04/genetic-study-uncovers-causes-of-alzheimer-s-disease-115875-23036111/; The Independent, 4.4.11, http://www.independent.co.uk/news/science/a-test-for-alzheimers-disease-ndash-but-will-anyone-want-to-take-it-2261426.html; The Telegraph, 4.4.11, www.telegraph.co.uk/health/healthnews/8422477/New-genes-found-in-hunt-for-Alzheimers-disease-cure.html; Daily Mail, 4.4.11, www.dailymail.co.uk/health/article-1373063/The-genetic-clues-help-prevent-Alzheimers-disease.html?ito=feeds-newsxml;


Unknown
Year(s) Of Engagement Activity 2011
 
Description ART - Westminster 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/parliamentarians
Results and Impact Dissemination of research findings to parliamentarians

not known
Year(s) Of Engagement Activity 2010
 
Description ART Event - Bournemouth 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? Yes
Geographic Reach Regional
Primary Audience Participants in your research and patient groups
Results and Impact Disseminating research findings to research participants

not know
Year(s) Of Engagement Activity 2009
 
Description ART Public Lecture 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Presented research findings as part of the ART public lecture "New Alzheimer's genes: What do they mean?"

Not Known
Year(s) Of Engagement Activity 2010
 
Description Alzheimer's Research UK trustee talk and lab tour 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Presentation for lay members of Alzheimer's Research UK

unknown
Year(s) Of Engagement Activity 2012
 
Description Alzheimers Society Visit 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Health professionals
Results and Impact presented research findings to representatives of ART at a visit hosted by the Dean of Medicine, Cardiff University

not known
Year(s) Of Engagement Activity 2010
 
Description Annual ART Conference 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Participants in your research and patient groups
Results and Impact Attended and presented at the annual ART conference

not known
Year(s) Of Engagement Activity 2010
 
Description Awarded £800K to lead new genetic research into Alzheimer's 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact Professor Julie Williams, School of Medicine, has been awarded £800K to lead new genetic research into Alzheimer's (Business Weekly, 14.10.10)


Unknown
Year(s) Of Engagement Activity 2010
 
Description British Neuroscience Conference, Harrogate 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Finding genes for developmental dyslexia

unknown
Year(s) Of Engagement Activity 2011
 
Description Building CanadaUK collaborations in neurodegenerative disease 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach International
Primary Audience Policymakers/parliamentarians
Results and Impact Seminar at the High Comission of Canada

unknown
Year(s) Of Engagement Activity 2012
 
Description CADR Annual Public Conference, 5th October 2016 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact The Centre for Aging and Dementia Research (CADR) annual public meeting was held on 5th October in City Hall, Cardiff. A variety of individuals attended including the general public, and NHS staff working in dementia. Feedback received indicated that the event was regarded as training for NHS staff. Discussion groups were lively, and focused on clinical dementia. A number of information stands were manned during the meeting, including an ARUK stand, a Cardiff University Alzheimer's Team Recruitment stand, a Join Dementia Research (JDR) Stand, and a variety of others. The Cardiff research team have had an increased number of volunteer queries. We have also furthered collaborations with CFAS Wales, Dr John Hindle (DLB/PD expert) and others as a direct result of this meeting.
Year(s) Of Engagement Activity 2016
URL http://www.cadr.cymru/en/
 
Description CNS Leadership Seminar: The quest to slow Alzheimer's disease progression 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Provided a talk entitled "Genetic basis of Alzheimer disease susceptibility" at the CNS Leadership Seminar: The quest to slow Alzheimer's disease progression

Unknown
Year(s) Of Engagement Activity 2013
URL http://onenucleus.com/onenucleus-events?id=692
 
Description Calling for more funding for research into dementia 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Media (as a channel to the public)
Results and Impact Professor Julie Williams and Professor Mike Owen, Cardiff University are calling for more funding for research into dementia. (Western Mail, 9/2/11, p5)


Unknown
Year(s) Of Engagement Activity 2011
 
Description Cardiff Scientific Society 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Talk entitled - The Genetics underlying late-onset Alzheimer's Disease

Not Known
Year(s) Of Engagement Activity 2010
 
Description Cardiff experts call for Alzheimer's action 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Cardiff experts have been at the forefront of calls to step up the battle against Alzheimer's Disease in the press and on national television following a leading international conference on the disease. Nationwide media coverage including the BBC news

Will lead to increased public awareness
Year(s) Of Engagement Activity 2010
 
Description Defining the genetic architecture of AD 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Health professionals
Results and Impact Rome 28th February 2011 - Invited speaker


Unknown
Year(s) Of Engagement Activity 2011
 
Description Defining the genetic architecture of Alzheimer's disease 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Health professionals
Results and Impact Alzheimer's Research Trust Research Day - Manchester ART Centre, Chancellors conference centre 27th January 2011 - Keynote speaker


Unknown
Year(s) Of Engagement Activity 2011
 
Description Defining the genetic architecture of Alzheimer's disease 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Royal College of Psychiatrists International Congress 29th June 2011 - Invited speaker


Unknown
Year(s) Of Engagement Activity 2011
 
Description Defining the genetic architecture of Alzheimer's disease 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Presentation for the Waterloo foundation

unknown
Year(s) Of Engagement Activity 2012
 
Description Defining the genetic architecture of Alzheimer's disease 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Health professionals
Results and Impact College of Mental Health Pharmacy , Leicestershire 30th September 2011 - Keynote speaker


Unknown
Year(s) Of Engagement Activity 2011
 
Description Defining the genetic architecture of Alzheimer's disease 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Health professionals
Results and Impact German National Genome Research Network (NGFN) Conference - 27th September 2011 - Keynote speaker


Unknown
Year(s) Of Engagement Activity 2011
 
Description Dementia - A National Symposium 2013 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Delivered a talk entitled "Identifying and understanding genes which increase the risk of developing Alzheimer's disease and other dementias"

Unknown
Year(s) Of Engagement Activity 2013
URL http://www.open.ac.uk/science/main/files/science/file/Dementia%202013%20-%20Programme.pdf
 
Description Dementia research at the Cardiff City stadium 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Media (as a channel to the public)
Results and Impact Professor Julie Williams, School of Medicine, will be among a set of leading speakers discussing dementia research at the Cardiff City stadium today (South Wales Echo, 22.05.11, Pg 10)


Unknown
Year(s) Of Engagement Activity 2011
 
Description Dementia: Making a Difference. Television Programme for BBC2 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact Television programme about the work of Julie Williams http://www.bbc.co.uk/programmes/b01j0qwr

unknown
Year(s) Of Engagement Activity 2012
 
Description Distribution of news letter 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? Yes
Geographic Reach Regional
Primary Audience Participants in your research and patient groups
Results and Impact We distribute a 4-8 page newsletter annually to participants in our research, their families and healthcare professionals At present just over 1000 people receive our newsletter.

The newsletter helps engage the public in our research and we receive a large amount of positive feedback from it. We also hope that the newsletter has a positive impact on retention of participants in longitudinal aspects of our research.
Year(s) Of Engagement Activity 2006,2007,2008,2009,2010
 
Description EISA Conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Health professionals
Results and Impact Delivered talk entitled - Dementia and Cognitive Dysfunction

Unknown
Year(s) Of Engagement Activity 2010
 
Description Eli Lilly Seminar 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Defining the genetic architecture of Alzheimer's Disease

unknown
Year(s) Of Engagement Activity 2011
 
Description Finding genes for developmental dyslexia 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Health professionals
Results and Impact 7th International Conference - British Dyslexia Association 2 - 5th June 2011 - Invited speaker


Unknown
Year(s) Of Engagement Activity 2011
 
Description Finding the causes of Alzheimer's disease 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Delivered a public lecture as part of the Science in Health Public Lecture Series entitled "Finding the causes of Alzheimer's disease"

Unknown
Year(s) Of Engagement Activity 2013
URL http://medicine.cf.ac.uk/event/finding-the-causes-of-alzheimers-disease/
 
Description Fiona Phillips visit 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact Journalist and broadcaster Fiona Phillips is to visit the University's MRC Centre for Neuropsychiatric Genetics and Genomics this week to investigate leading Alzheimer's research. (South Wales Echo, 21.07.11, p.9)


Unknown
Year(s) Of Engagement Activity 2011
 
Description Funding for Alzheimer's research 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact Scientists in Wales researching the causes of dementia are at a "major disadvantage" because the nation does not fund such projects says Professor Julie Williams, School of Medicine. (Western Mail, 4/2/10, p14) Professor Williams is also interviewed about funding for Alzheimer's research.  (BBC Wales News, 4/2/10)


Unknown
Year(s) Of Engagement Activity 2009
 
Description Funding for Alzheimer's research 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Media (as a channel to the public)
Results and Impact Professor Julie Williams, School of Medicine, is interviewed regarding funding for Alzheimer's research.  (BBC Radio Wales, 2.2.10)


Unknown
Year(s) Of Engagement Activity 2010
 
Description Funding for medical research is dangerously low 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact Professor Julie Williams, School of Medicine, says funding for medical research is dangerously low. (Daily Telegraph 9.2.11 http://www.medicalnewstoday.com/articles/216363.php )


Unknown
Year(s) Of Engagement Activity 2011
 
Description Further insights into the causes of Alzheimer's disease 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact UN Older Persons' Day - 29th Sept 2011 - Invited speaker


Unknown
Year(s) Of Engagement Activity 2011
 
Description GEHC/CU Symposium 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Local
Primary Audience Third sector organisations
Results and Impact Provided a talk entitled "Opportunities in Wales: WG" at the Joint GE Healthcare / Cardiff University Symposium (Theme: Stem Cell technologies)

Unknown
Year(s) Of Engagement Activity 2013
 
Description Genetic discoveries pinpoint new causes for Alzheimer's disease 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Alzheimer's Society, Wales Regional Conference 14th July 2011 - Invited speaker


Unknown
Year(s) Of Engagement Activity 2011
 
Description Genetic modifiers workshop 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Progress in neurodegenerative disorders

Unknown
Year(s) Of Engagement Activity 2011
 
Description Genetics of Alzheimer's Disease and its translation 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Neurodem Research Development Group presentation on Genetics of Alzheimer's Disease

unknown
Year(s) Of Engagement Activity 2012
 
Description Genome wide association study of Alzheimer's disease 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Health professionals
Results and Impact Invited Plenary - International Conference on Alzheimer's disease (ICAD) - Vienna - July 2009


Unknown
Year(s) Of Engagement Activity 2009
 
Description Global media coverage 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact In September 2009 we published evidence of two new genes which are associated with susceptibility to Alzheimer's disease. This research generated substantial media interest both nationally and internationally. To see the BBC coverage of this story please visit: http://news.bbc.co.uk/1/hi/wales/8239773.stm. The story was covered in over 70 high quality publications (a full list is provided at the bottom this text). In addition, these findings have recently been recognised as one of the world's top 10 scientific breakthroughs of 2009 by Time magazine. See: http://www.time.com/time/specials/packages/article/0,28804,1945379_1944376_1944408,00.html Publications: Sky News Channel 4 News BBC Wales News ITV Wales Pittsburgh post - Gazette Daily Express Swansea Sound Washington Post New York Times Daily Telegraph Western Mail South Wales Echo The Independent The Irish Times Financial Times Sydney Morning Herald Ottawa Citizen Daily Mail Guardian The Mirror Nottingham Journal The Money Times The Sun Sindh Today Science Daily Belfast Telegraph Emax Health Malaysia News net Digital Journal Cambridge News Online Alzheimer's Society Real Radio Red Dragon Boston Globe Calgary Sun Norwich Evening News The Gov Monitor The Spokesman Review Food consumer Times of India Science News Medical News Today Top News NHS News Nature.com Blog Efitness.now Merinews Science Alert Pulse Today AHN Richmond Times - Dispatch The Birmingham News, Alabama Newsday, Melville NY The San Diego Union - Tribune, California El Nuevo Herald The Daily Gazette, New York St Paul's Pioneer Press Valley News Dispatch Chattanooga Times Free Press St Petersburg Times The Virginian - Pilot The Providence Journal The Gainsville Sun San Jose Mercury News The Journal Gazette Daily Times - Call The Tribune Visit Bulgaria Australian Ageing Agenda The News - Enterprise Ethiopian Review The Times - Tribune, PA South Florida Sun Sentinel ABC7 St Charles County Business Record The St Louis Countian

Such extensive media coverage has raised the profile of Alzheimer's disease and dementia research. Since the articles were published we have received numerous enquiries from members of the public wanting to contribute to our research. It has also promoted our own research nationally and internationally and we have developed collaborations as a direct result of this media coverage.
Year(s) Of Engagement Activity 2009
 
Description Grandround presentation - NHS Cardiff Postgraduate Centre 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Regional
Primary Audience Health professionals
Results and Impact Defining the genetic architecture for Alzheimer's Disease

unknown
Year(s) Of Engagement Activity 2011
 
Description House of Commons presentation 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Policymakers/parliamentarians
Results and Impact Alzheimer's Disease - causes, research

unknown
Year(s) Of Engagement Activity 2012
 
Description House of Lords Lunch 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Policymakers/parliamentarians
Results and Impact Lunch discussion at The House of Lords

unknown
Year(s) Of Engagement Activity 2012
 
Description ICAD, Paris 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Role of the Immune System and Inflammatory Response in the Aetiology of Alzheimer's Disease

unknown
Year(s) Of Engagement Activity 2011
 
Description IWA's Agenda magazine 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact Professor Julie Williams' Alzheimer's research is featured in the summer edition of IWA's Agenda magazine (Agenda, No 41 Agenda, Front Page and Pgs 48-49)


Unknown
Year(s) Of Engagement Activity 2010
 
Description International Genomics of Alzheimer's Project 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact A group led by Professor Julie Williams, School of Medicine is one of four involved in the International Genomics of Alzheimer's Project - a collaboration formed to discover and map the genes that contribute to Alzheimer's disease. http://www.medicalnewstoday.com/articles/215425.php


Unknown
Year(s) Of Engagement Activity 2011
 
Description Interview with ITV news 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Media (as a channel to the public)
Results and Impact Julie Williams was interviewed by ITV news in the HEB labs regarding Alzheimer's disease research
Year(s) Of Engagement Activity 2015
 
Description It is time to make mental health research a funding priority 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Media (as a channel to the public)
Results and Impact Professor Julie Williams, School of Medicine, argues in an essay that it is time to make mental health research a funding priority. Cardiff University has committed to this in creating the new Neuroscience and Mental Health Research Institute - and Professor Williams calls on other decision makers and funders to do likewise. (W.Mail, 9.8.10 p26)


Unknown
Year(s) Of Engagement Activity 2010
 
Description Kings College London Seminar 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Health professionals
Results and Impact Delivered talk entitled - Psychiatric Genetics: Everything you always wanted to know but were afraid to ask

Unknown
Year(s) Of Engagement Activity 2010
 
Description Llandough Hospital 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Health professionals
Results and Impact Dissemination of recent findings

not known
Year(s) Of Engagement Activity 2009
 
Description Marshall Scholars 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Schools
Results and Impact A talk entitled "New genetic findings in Alzheimers Disease" was presented to a group of Marshall Scholars

not known
Year(s) Of Engagement Activity 2010
 
Description NGFN Symposium - Bonn 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Health professionals
Results and Impact Delivered talk entitled - Molecular Genetics in Alzheimer's Dementia

Unknown
Year(s) Of Engagement Activity 2010
 
Description New Alzheimer's genes revealed 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Two potentially key genes linked to the development of Alzheimer's disease have been uncovered by UK researchers. Covered by major news channels including the BBC

Nationwide media coverage will lead to increased public knowledge
Year(s) Of Engagement Activity 2010
 
Description New breakthrough in Alzheimer's research 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact Professor Julie Williams, School of Medicine, comments on a new breakthrough in Alzheimer's research which has seen scientists unravel the precise function of genes known to make people more at risk of developing the illness. (Daily Express, 28.10.11, p.17)


Unknown
Year(s) Of Engagement Activity 2011
 
Description New susceptibility genes for Alzheimer's disease 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Health professionals
Results and Impact Invited speaker - Eisai Symposium in Neuroscience (Dementia and Cognitive Dysfunction) - May 2010


Unknown
Year(s) Of Engagement Activity 2010
 
Description Oxford Seminar Series 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Health professionals
Results and Impact Invited speaker - Seminar Series,University of Oxford - June 2010


Unknown
Year(s) Of Engagement Activity 2010
 
Description Pratchett play for Alzheimer's 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact A researcher at Cardiff University's National Centre for Mental Health has produced a play adapted from a Terry Pratchett novel in a bid to raise money for Alzheimer's Research UK.


Unknown
Year(s) Of Engagement Activity 2013
URL http://www.cardiff.ac.uk/news/articles/pratchett-play-for-alzheimers-11246.html
 
Description Probus Cardiff 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Provided a talk at the Combined Probus Club of Cardiff Inc.

Increased public awareness of Alzheimer's research
Year(s) Of Engagement Activity 2012
 
Description Public Meeting 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? Yes
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact We hosted a public meeting, supported by the Alzheimer's Research Trust, in September 2007. In addition to events hosted within the University we have also presented our research findings to carers, and individuals with AD at Alzheimer's Society regional meetings in Cardiff, Swansea, Blackwood and Caerleon and to the members of the Newport Carers Group and County Hosptial Carers Group, Pontypool.

These meetings contribute substantially to engaging the public in our research.
Year(s) Of Engagement Activity 2007
 
Description Radio discussion 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Regional
Primary Audience Media (as a channel to the public)
Results and Impact BBC Radio Wales Jason Mohammed show discussing progress in Alzheimer's Disease Research

unknown
Year(s) Of Engagement Activity 2012
 
Description Researchers Find Two More Genetic Risk Factors For Alzheimer's Disease 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Widespread worldwide broadcast, press and online coverage of a major new study into Alzheimer's led by researchers at Cardiff University. Including BBC, Channel 4, SKY and ABC news, The Telegraph, The Times, The Telegraph, The New York Times and all over major news channels / papers.

"The MRC Centre and research like this is changing our understanding of what causes the common form of Alzheimer's disease and provides valuable new leads in the race to find treatments and possibly cures.

"It also shows that other genes can be identified using this method, and we are already planning a larger study involving 60,000 people, which can be achieved within the next year.

"It is also important to recognise the contribution many Welsh people who have acted as subjects for this research over the years."
Year(s) Of Engagement Activity 2009,2010
 
Description Rugby legend's research donation 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact A Wales and British Lions rugby legend will help boost the University's world-leading Alzheimer's research by chipping-in with a charity donation.

Charitable donation received
Year(s) Of Engagement Activity 2013
URL http://www.cardiff.ac.uk/news/articles/rugby-legends-research-donation-9461.html
 
Description Scientists at Cardiff University say they are a step closer to understanding the causes of dementia 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact Scientists at Cardiff University say they are a step closer to understanding the causes of dementia, thanks to a grant of nearly £250,000. The money will fund its brain bank, a centre which encourages people to donate their brains for medical research. Professor Julie Williams comments (BBC Wales On-line, 04.07.2013

Unknown
Year(s) Of Engagement Activity 2013
URL http://www.bbc.co.uk/news/uk-wales-22288025
 
Description Seven preventable risk factors which can be attributed to Alzheimer's disease 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Media (as a channel to the public)
Results and Impact Professor Julie Williams, School of Medicine, comments on a new study by scientists in the US which shows seven preventable risk factors which can be attributed to Alzheimer's disease. (Western Mail, 20.07.11, p.10); (South Wales Echo, 20.07.11, p.20)


Unknown
Year(s) Of Engagement Activity 2011
 
Description The Academy of Medical Sciences, Cardiff 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Successful collaborations with basic scientists


unknown
Year(s) Of Engagement Activity 2011
 
Description The Alzheimer's Society first all-Wales conference in Swansea 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Media (as a channel to the public)
Results and Impact Professor Julie Williams, School of Medicine, was a keynote speaker on the genetic causes of Alzheimer's at the Alzheimer's Society first all-Wales conference in Swansea. (W.Mail 12.7.11 p12)


Unknown
Year(s) Of Engagement Activity 2011
 
Description The First Minister for Wales Carwyn Jones has appointed Cardiff University's Professor Julie Williams, School of Medicine, as Wales' Chief Scientific Adviser. 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact The First Minister for Wales Carwyn Jones has appointed Cardiff University's Professor Julie Williams, School of Medicine, as Wales' Chief Scientific Adviser.

Unknown
Year(s) Of Engagement Activity 2013
 
Description The International Genomics of Alzheimer's Project (IGAP) 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact A leading University expert in identifying genes that cause Alzheimer's disease will meet with some of the world's other figures for the first-time in Paris (Friday 19th November) in a bid help share knowledge and speed-up the genetic fight against the disease. The International Genomics of Alzheimer's Project (IGAP) is a major international consortium which brings together for the first time four of the world's leading research centres - including  Professor Julie Williams, School of Medicine, who leads the Genetic and Environmental Risk in Alzheimer's Disease (GERAD).


Unknown
Year(s) Of Engagement Activity 2010
 
Description The International Genomics of Alzheimer's Project (IGAP) 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact The International Genomics of Alzheimer's Project (IGAP) - a group of leading experts in Alzheimer's research from Europe, USA and the rest of the world has been established. The new international group includes Professor Julie Williams, School of Medicine (PR Newswire, 01.02.11, www.prnewswire.com/news-releases/first-international-collaboration-on-the-genetics-of-alzheimers-disease-is-launched-114989074.html)


Unknown
Year(s) Of Engagement Activity 2011
 
Description The Today Programme 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact JW on BBC Radio 4's Today programme talking
about her discovery of two new genes associated with Alzheimer's disease which could provide
valuable new leads in the race to find treatments and possibly cures for the devastating condition

Unknown
Year(s) Of Engagement Activity 2009
 
Description Time Magazine - Medical breakthroughs of 2009 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact A key University study which helped uncover two new genes associated with Alzheimer's disease has been recognised as one of the top 10 medical breakthroughs of 2009 by TIME Magazine.

International acknowledgement of research findings.
Year(s) Of Engagement Activity 2009
 
Description U3A Brecon 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Participants in your research and patient groups
Results and Impact Dissemination of Alzheimers research findings

not known
Year(s) Of Engagement Activity 2010
 
Description UN Older Persons Day - Cardiff 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Delivered talk entitled - Will identifying susceptibility genes for Alzheimer's Disease increase healthy aging?

Unknown
Year(s) Of Engagement Activity 2010
 
Description US Fulbright Scholars Forum 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Spoke at the US Fulbright Scholars Forum .
Each year the Fulbright Awards team organise a week-long Forum for current US postgraduates and scholars to get together and explore a different part of the country. This January, over fifty grantees descended on the cities of Bristol and Cardiff to explore Wales and the West Country. Fulbright was generously hosted by the University of Bristol and the University of Cardiff who helped put on an excellent series of events.

Unknown
Year(s) Of Engagement Activity 2013
URL https://www.bfsa.org/wales
 
Description Un o Bob Tri (One of Every Three) Television Programme for S4C 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Regional
Primary Audience Media (as a channel to the public)
Results and Impact Interview for TV programme http://www.s4c.co.uk/ffeithiol/e_un_bob_tri.shtml

unknown
Year(s) Of Engagement Activity 2012
 
Description University's work on Alzheimer's 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Media (as a channel to the public)
Results and Impact Professor Julie Williams, School of Medicine, discusses the University's work on Alzheimer's. (BBC Radio Wales 17.2.11)


Unknown
Year(s) Of Engagement Activity 2011
 
Description Update on medical and scientific advances in prevention and treatment of dementia 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Health professionals
Results and Impact UK dementia Congress Plenary: Update on medical and scientific advances in previention and treatment of dementia

unknown
Year(s) Of Engagement Activity 2012
 
Description WAG Seminar 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Policymakers/parliamentarians
Results and Impact Presented recent research findings to policy makers

not known
Year(s) Of Engagement Activity 2010
 
Description Wales Gene Park 10th Anniversary, Cardiff "Defining the genetic architecture of Alzheimer's disease" 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Provided a talk entitled "Defining the Genetic Architecture of Alzheimer's Disease"

Unknown
Year(s) Of Engagement Activity 2013
URL http://www.walesgenepark.cardiff.ac.uk/wp-content/uploads/2013/04/4_Julie_Williams.pdf
 
Description Welsh language champions in NHS health boards 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Media (as a channel to the public)
Results and Impact Professor Julie Williams, School of Medicine comments on plans to appoint Welsh language champions in NHS health boards. (Western Mail, 7/6/10, p25)


Unknown
Year(s) Of Engagement Activity 2010
 
Description Westminster visit - Dementia 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/parliamentarians
Results and Impact Dissemination of research findings to parliamentarians

not known
Year(s) Of Engagement Activity 2009
 
Description Will identifying susceptibility genes for Alzheimer's disease increase healthy ageing? 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Invited speaker - United Nations Older Person's Day - Promoting active and healthy ageing - Cardiff, 30th September 2010


Unknown
Year(s) Of Engagement Activity 2010
 
Description Zeurs Austria - Drugs Genetics 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/parliamentarians
Results and Impact Presented talk entitled - Defining the genetic architecture for AD

not known
Year(s) Of Engagement Activity 2009
 
Description the country needs more scientists 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Wales' new chief scientific adviser, Prof Julie Williams, says the country needs more scientists. The Merthyr-born academic was appointed a CBE for her Alzheimer's research at the School of Medicine in Cardiff, and her appointment was announced last month (BBC Wales Today; BBC Wales On-line, 16.09.2013

Unknown
Year(s) Of Engagement Activity 2013
URL http://www.bbc.co.uk/news/uk-wales-24111210#?utm_source=twitterfeed&utm_medium=twitter